Table 1.
Demographics and Baseline Characteristics (n = 60)
Characteristic | No. | % | |
---|---|---|---|
Age, years | |||
Median | 59 | ||
Range | 26-84 | ||
Race/ethnicity | |||
White | 47 | 78 | |
Black | 5 | 8 | |
Hispanic | 5 | 8 | |
Asian | 3 | 5 | |
Male sex | 35 | 58 | |
ECOG performance status | |||
0 | 24 | 40 | |
1 | 36 | 60 | |
Histology | |||
Papillary | 30 | 50 | |
Follicular/Hürthle cell variant | 15/11 | 25/18 | |
Medullary | 11 | 18 | |
Anaplastic | 2 | 3 | |
Other* | 2 | 3 | |
Current disease stage | |||
IV | 30 | 50 | |
Recurrent | 30 | 50 | |
Received previous treatment | 56 | 93 | |
Surgery | 52 | 87 | |
Radiotherapy | 49 | 82 | |
131I | 43 | 72 | |
Chemotherapy | 9 | 15 | |
Investigational therapy | 5 | 8 | |
Chemotherapy/immunotherapy | 1 | 2 | |
Immunotherapy, biologic | 1 | 2 | |
Other | 8 | 13 | |
Treatment-naive | 4 | 7 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; 131I, radioactive iodine.
One patient each had insular carcinoma and neuroendocrine carcinoma.